Granulomatosis with Polyangiitis clinical trials at University of California Health

2 research studies open to eligible people

Showing trials for

  • Iptacopan in Patients With ANCA Associated Vasculitis

    open to eligible people ages 18-100

    The purpose of this study is to evaluate the efficacy and safety of iptacopan compared to standard of care (SOC) to induce and maintain remission in study participants with active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA), when used in combination with rituximab (RTX) induction. The trial will also assess the impact of iptacopan on disease relapses, evolution of renal function and proteinuria, GC side effects, patients' immune status, and QoL.

    at UCLA

  • Longitudinal Study for Eosinophilic Granulomatosis With Polyangiitis

    open to all eligible people

    Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare immune system disorder that causes asthma, an excessive number of eosinophils (a type of white blood cell) in the blood, and the inflammation of blood vessels, or vasculitis. In order to properly treat EGPA, it is critical that the level of disease activity can be determined over the course of the disease. The purpose of this study is to determine new biological markers, or biomarkers, that may be used to assess the severity of this disease in people with EGPA.

    at UCSD

Our lead scientists for Granulomatosis with Polyangiitis research studies include .

Last updated: